The Contraceptive CHOICE Project, a research study at Washington University in St. Louis, found that offering long-acting, reversible contraception (LARC) to women first, citing its low-failure rates, reduced rates of unintended pregnancy and abortion and increased continuation rates.
The female hormone megestrol acetate (MA) improves appetite and is associated with slight weight gain in patients with cancer, AIDS, and other underlying pathology, but comes with significant adverse events.
The FDA has approved an application to market the emergency contraceptive Plan B One-Step for use without a prescription by women 15 years of age and older.
The use of a postoperative levonorgestrel-releasing intrauterine device reduces the recurrence of painful periods in women with endometriosis.
Women with endometriosis who undergo surgery to treat the condition are less likely to have ovarian cancer develop later in life.
Plan B and other levonorgestrel-based emergency contraception will be available over-the-counter without age restrictions.
Immediate start of hormonal contraception may reduce unintended pregnancies and increase method continuation, but the evidence is limited, according to the findings of an intervention review conducted by the Cochrane Fertility Regulation Group.
Women who have migraine with aura, especially those who take combined hormonal contraceptives (CHCs) have an increased risk for cardiovascular or thrombotic events.
From ASRM’s removal of the ‘experimental’ label from the procedure of oocyte cryopreservation, to discoveries into the complex genetic processes involved in ovarian cancer, 2012 was another important year in ob/gyn research. Here, the leaders of seven major ob/gyn societies reflect on the most exciting research of the last year.
Evaluation of a patient’s lipid profile before prescribing a combined oral contraceptive could be justified by the high prevalence of dyslipidemia, concludes a new study.